Taha Safa, Sultan Ameera, Aljishi Muna, Greish Khaled
Princess Al-Jawhara Center for Molecular Medicine, Genetics and Inherited Diseases, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 26671, Bahrain.
Int J Mol Sci. 2025 Jul 27;26(15):7269. doi: 10.3390/ijms26157269.
This study investigates the effects of copper nanoparticles (CuNPs) on KRT19 gene expression in four breast cancer cell lines (MDA-MB-231, MDA-MB-468, MCF7, and T47D), representing triple-negative and luminal subtypes. Using cytotoxicity assays, quantitative RT-PCR, and bioinformatics tools (STRING, g:Profiler), we demonstrate subtype-specific, dose-dependent KRT19 suppression, with epithelial-like cell lines showing greater sensitivity. CuNPs, characterized by dynamic light scattering (DLS) and transmission electron microscopy (TEM) with a mean size of 179 ± 15 nm, exhibited dose-dependent cytotoxicity. Bioinformatics analyses suggest KRT19's potential as a biomarker for CuNP-based therapies, pending in vivo and clinical validation. These findings highlight CuNPs' therapeutic potential and the need for further studies to optimize their application in personalized breast cancer treatment.
本研究调查了铜纳米颗粒（CuNPs）对四种乳腺癌细胞系（MDA-MB-231、MDA-MB-468、MCF7和T47D）中KRT19基因表达的影响，这些细胞系代表三阴性和管腔亚型。通过细胞毒性测定、定量逆转录聚合酶链反应（RT-PCR）和生物信息学工具（STRING、g:Profiler），我们证明了KRT19的抑制具有亚型特异性和剂量依赖性，上皮样细胞系表现出更高的敏感性。通过动态光散射（DLS）和透射电子显微镜（TEM）表征的平均尺寸为179±15nm的CuNPs表现出剂量依赖性细胞毒性。生物信息学分析表明，KRT19有潜力作为基于CuNP疗法的生物标志物，但有待体内和临床验证。这些发现突出了CuNPs的治疗潜力以及进一步研究以优化其在个性化乳腺癌治疗中应用的必要性。
